$$$
{{ $t($store.state.user.experience_value_in_dollars) }}
Senior
{{ $t($store.state.user.experience_search_name) }}
0
jobs
Strong editing and English writing skills for bioscience articles, Master's and PhD thesis
Laurel Tabe Bate-Eya, PhD
,
Oxford, United Kingdom
Experience
Other titles
Skills
I'm offering
I am called Laurel, I am a Postdoctoral scientist at the Department of Oncology at the University of Oxford. I have 12 years of experience in laboratory analytics skills, 7 years of experience in bioinformatics data analysis (RNASeq, Affymetrix profiling), 5 years editing Masters and Ph.D. thesis for students in the Bioscience field and experience in writing and publishing articles in peer-reviewed journals.
Markets
United Kingdom
(Remote
only)
France
(Remote
only)
Language
English
Fluently
French
Fluently
Dutch
Good
Ready for
Larger project
Ongoing relation / part-time
Available
My experience
2017 - ?
job
Postdoctoral scientist
The Department of Oncology, University of Oxford.
Department: Oncology
Research Interest:
Targeting PRMT5 in neuroblastoma using small molecule inhibitors.
1. In this research project, we performed the in vitro and in vivo pre-clinical evaluation of novel PRMT5 inhibitors, comparing the response to the based on the MYCN status of the neuroblastoma samples. We explore the importance of the alternative splicing machinery as a biomarker of efficacy of the PRMT5 inhibitors in neuroblastoma. The outcome of this project will potentially lead to the pre-clinical evaluation of these inhibitors in neuroblastoma patients with a positive MYCN amplification status.
Determining mechanisms of resistance to anti-angiogenic therapy in breast cancer.
1. In this study, we performed single-cell and next generation sequencing of primary tumours and mice xenografts with and without vessel co-option to determine the gene expression profile of these tumours and genes promoting resistance to anti-angiogenic therapies.
2. Pre-clinical evaluation of PFKFB3 inhibitors was performed in vitro in breast cancer and HUVECs primary cell lines to determine the efficacy of these compounds in cell lines with high expression of this protein.
Research Interest:
Targeting PRMT5 in neuroblastoma using small molecule inhibitors.
1. In this research project, we performed the in vitro and in vivo pre-clinical evaluation of novel PRMT5 inhibitors, comparing the response to the based on the MYCN status of the neuroblastoma samples. We explore the importance of the alternative splicing machinery as a biomarker of efficacy of the PRMT5 inhibitors in neuroblastoma. The outcome of this project will potentially lead to the pre-clinical evaluation of these inhibitors in neuroblastoma patients with a positive MYCN amplification status.
Determining mechanisms of resistance to anti-angiogenic therapy in breast cancer.
1. In this study, we performed single-cell and next generation sequencing of primary tumours and mice xenografts with and without vessel co-option to determine the gene expression profile of these tumours and genes promoting resistance to anti-angiogenic therapies.
2. Pre-clinical evaluation of PFKFB3 inhibitors was performed in vitro in breast cancer and HUVECs primary cell lines to determine the efficacy of these compounds in cell lines with high expression of this protein.
Research, Protein
2016 - 2017
job
Research Scientist
Princess Maxima Centre for Pediatric Oncology.
Department: Translational Medicine
Research Interest: Overcoming ABT199 mediated resistance in neuroblastoma
In this study, firstly we explore different mechanisms of resistance to the BCL-2 specific inhibitors ABT199 in neuroblastoma tumors. Secondly, we explore how to overcome these resistance mechanisms with combinational therapy using chemotherapeutics and targeted compounds for the treatment of neuroblastoma. We additionally evaluate selection biomarkers for sensitivity and efficacy of ABT199 in neuroblastoma and future inclusion criteria's of neuroblastoma patients for phase I clinical trials of ABT199.
Research Interest: Overcoming ABT199 mediated resistance in neuroblastoma
In this study, firstly we explore different mechanisms of resistance to the BCL-2 specific inhibitors ABT199 in neuroblastoma tumors. Secondly, we explore how to overcome these resistance mechanisms with combinational therapy using chemotherapeutics and targeted compounds for the treatment of neuroblastoma. We additionally evaluate selection biomarkers for sensitivity and efficacy of ABT199 in neuroblastoma and future inclusion criteria's of neuroblastoma patients for phase I clinical trials of ABT199.
Research
2010 - 2016
temp
PhD student
Academic Medical Centre, University of Amsterdam.
Department: Oncogenomics
Research Interest: Mammalian tumour cell line generation, targeted drug development and drug delivery systems in neuroblastoma.
Brief Synopsis of Research:
1. In vitro validation of current molecular biology techniques and targeted drug development and validation is specifically carried out in 2D cultured tumour cells that have been in culture for long periods of time. Over time, these 2D cultured cell lines have acquired non-tumour-related mutations and deregulated pathways which does not reflect the genomic landscape of the tumours from which the cells were originally derived from. Short-term 3D cultured tumour cells might better mimic the original tumour from which the cells were derived from. In this study, we carried out the isolation and culturing of new neuroblastoma tumour cells. We observed that these cell lines and their corresponding xenografts retain the genomic landscape originally found in the tumours from which the cell lines were derived from. These cell lines might thus be a better in vitro model to carry out pre-clinical drug development and validation studies.
2. The anti-apoptotic B cell lymphoma proteins are highly expressed and have been shown to have an oncogenic role in numerous cancer types. BCL-2 is highly expressed in neuroblastoma tumors and previous data show that knockdown and inhibition of BCL-2 with shRNA and small molecule inhibitor ABT263 induces an apoptotic phenotype in neuroblastoma cell lines. However, ABT263 is not BCL-2 specific and also inhibits BCL-XL and BCL-W leading to dose-limiting thrombocytopenia in patients treated with ABT263.In this study, we characterized the response of neuroblastoma cell lines and xenografts with high BCL-2 expression to the new and specific BCL-2 inhibitor ABT199 in vitro and in vivo in neuroblastoma.
3. Whole gains of chromosome 7 have been observed in 40-60% neuroblastoma tumors. A local gain of the enhancer of zeste homologue 2 (EZH2) gene located in chromosome 7q35 and subsequently its overexpression has been observed in neuroblastoma tumors. In this study, we characterize the response of neuroblastoma cell lines with high EZH2 expression to the EZH2-specific histone methyltransferase inhibitors GSK126 and EPZ6438. We show that downregulation of EZH2 protein levels by shRNA's lead to a strong apoptotic phenotype which can be rescued by overexpressing EZH2ΔSET a truncated mutant protein of the EZH2 wild type protein lacking histone methyltransferase activity highlighting the need to develop drugs that specifically target the EZH2 protein as a whole which might be beneficial in the future treatment of neuroblastoma patients with high EZH2 expression.
Job activities and studies
❖ Isolation and generation of mammalian cell lines
❖ Western blot
❖ Gene expression study and analysis
❖ Animal models in research (Mice). Article 9: Yes
❖ Cell culture (2D and 3D)
❖ Flow cytometry
❖ Apoptosis/proliferation assay
❖ PCR, qPCR, Chromatin-Immunoprecipitation (ChIP)
❖ Next generation sequencing
❖ Immunoprecipitation
❖ Signalling pathway identification, in- vivo and in- vitro
❖ MTT and Cyquant Assays
❖ Immunofluorescent/Immunohistochemistry/Microscopy
❖ Bacteriology
❖ Short Tandem Repeat profiling and analysis of primary cultured cell lines
❖ High through-put compound screening
❖ DNA and RNA isolation
❖ Gene expression systems
❖ Affymetrix profiling of cell lines and tumours
Research Interest: Mammalian tumour cell line generation, targeted drug development and drug delivery systems in neuroblastoma.
Brief Synopsis of Research:
1. In vitro validation of current molecular biology techniques and targeted drug development and validation is specifically carried out in 2D cultured tumour cells that have been in culture for long periods of time. Over time, these 2D cultured cell lines have acquired non-tumour-related mutations and deregulated pathways which does not reflect the genomic landscape of the tumours from which the cells were originally derived from. Short-term 3D cultured tumour cells might better mimic the original tumour from which the cells were derived from. In this study, we carried out the isolation and culturing of new neuroblastoma tumour cells. We observed that these cell lines and their corresponding xenografts retain the genomic landscape originally found in the tumours from which the cell lines were derived from. These cell lines might thus be a better in vitro model to carry out pre-clinical drug development and validation studies.
2. The anti-apoptotic B cell lymphoma proteins are highly expressed and have been shown to have an oncogenic role in numerous cancer types. BCL-2 is highly expressed in neuroblastoma tumors and previous data show that knockdown and inhibition of BCL-2 with shRNA and small molecule inhibitor ABT263 induces an apoptotic phenotype in neuroblastoma cell lines. However, ABT263 is not BCL-2 specific and also inhibits BCL-XL and BCL-W leading to dose-limiting thrombocytopenia in patients treated with ABT263.In this study, we characterized the response of neuroblastoma cell lines and xenografts with high BCL-2 expression to the new and specific BCL-2 inhibitor ABT199 in vitro and in vivo in neuroblastoma.
3. Whole gains of chromosome 7 have been observed in 40-60% neuroblastoma tumors. A local gain of the enhancer of zeste homologue 2 (EZH2) gene located in chromosome 7q35 and subsequently its overexpression has been observed in neuroblastoma tumors. In this study, we characterize the response of neuroblastoma cell lines with high EZH2 expression to the EZH2-specific histone methyltransferase inhibitors GSK126 and EPZ6438. We show that downregulation of EZH2 protein levels by shRNA's lead to a strong apoptotic phenotype which can be rescued by overexpressing EZH2ΔSET a truncated mutant protein of the EZH2 wild type protein lacking histone methyltransferase activity highlighting the need to develop drugs that specifically target the EZH2 protein as a whole which might be beneficial in the future treatment of neuroblastoma patients with high EZH2 expression.
Job activities and studies
❖ Isolation and generation of mammalian cell lines
❖ Western blot
❖ Gene expression study and analysis
❖ Animal models in research (Mice). Article 9: Yes
❖ Cell culture (2D and 3D)
❖ Flow cytometry
❖ Apoptosis/proliferation assay
❖ PCR, qPCR, Chromatin-Immunoprecipitation (ChIP)
❖ Next generation sequencing
❖ Immunoprecipitation
❖ Signalling pathway identification, in- vivo and in- vitro
❖ MTT and Cyquant Assays
❖ Immunofluorescent/Immunohistochemistry/Microscopy
❖ Bacteriology
❖ Short Tandem Repeat profiling and analysis of primary cultured cell lines
❖ High through-put compound screening
❖ DNA and RNA isolation
❖ Gene expression systems
❖ Affymetrix profiling of cell lines and tumours
Research, 3D, Molecular biology, Development, 2D, Protein
2009 - 2009
internship
Student Internship
Åbo Akademie University.
Department: Research and Development
Research Interest: Mesoporous Silica Nanoparticles as Drug Delivery Systems to specifically target the Notch Signalling pathway in cancer.
Brief Synopsis of Research: Notch signaling, a key regulator of stem cells is frequently hyper-activated in cancer. It is often linked to aggressive forms of cancer, evading standard treatment; highlighting Notch as an exciting therapeutic target. Notch is in principle "druggable" by γ-secretase inhibitors (GSIs), inhibitory peptides and antibodies, but clinical use of Notch inhibitors is restricted by severe side effects and there is a demand for alternative cancer-targeted therapy. Here, we present a novel approach, using imageable mesoporous silica nanoparticles (MSNPs) as vehicles for targeted delivery of GSIs to block Notch signaling. Drug-loaded particles conjugated to targeting ligands induced cell-specific inhibition of Notch activity in vitro and exhibited enhanced tumor retainment with significantly improved Notch inhibition and therapeutic outcome in vivo.
Activities and studies
❖ Cell Culture
❖ PCR (gene specific and Overlapping)
❖ DNA and RNA isolation and purification
❖ DNA cloning/Plasmid design/Transformation
❖ Light Microscopy
❖ Confocal Microcopy
❖ Luciferase assays
❖ Western Blotting/SDS-PAGE/Bradford assay
❖ Making of Competent cells and Electroporation
❖ Immunoprecipitation
❖ Animal Experimentation
❖ Flow cytometry
Courses and trainings
❖ Cell Structures and Functions
❖ Genomes and Gene Expression
❖ Research Methods for Need Assessments
❖ Ethics of Life Science
❖ Scientific Writing in English
❖ Policy Research Project
❖ Policy, Management and Organisation in International Public Health
❖ Clinical Pharmacology for Exchange Students.
❖ Structure-based drug design
❖ Cellular Immunology
❖ Advanced Microscopy
Competence
Research Interest: Mesoporous Silica Nanoparticles as Drug Delivery Systems to specifically target the Notch Signalling pathway in cancer.
Brief Synopsis of Research: Notch signaling, a key regulator of stem cells is frequently hyper-activated in cancer. It is often linked to aggressive forms of cancer, evading standard treatment; highlighting Notch as an exciting therapeutic target. Notch is in principle "druggable" by γ-secretase inhibitors (GSIs), inhibitory peptides and antibodies, but clinical use of Notch inhibitors is restricted by severe side effects and there is a demand for alternative cancer-targeted therapy. Here, we present a novel approach, using imageable mesoporous silica nanoparticles (MSNPs) as vehicles for targeted delivery of GSIs to block Notch signaling. Drug-loaded particles conjugated to targeting ligands induced cell-specific inhibition of Notch activity in vitro and exhibited enhanced tumor retainment with significantly improved Notch inhibition and therapeutic outcome in vivo.
Activities and studies
❖ Cell Culture
❖ PCR (gene specific and Overlapping)
❖ DNA and RNA isolation and purification
❖ DNA cloning/Plasmid design/Transformation
❖ Light Microscopy
❖ Confocal Microcopy
❖ Luciferase assays
❖ Western Blotting/SDS-PAGE/Bradford assay
❖ Making of Competent cells and Electroporation
❖ Immunoprecipitation
❖ Animal Experimentation
❖ Flow cytometry
Courses and trainings
❖ Cell Structures and Functions
❖ Genomes and Gene Expression
❖ Research Methods for Need Assessments
❖ Ethics of Life Science
❖ Scientific Writing in English
❖ Policy Research Project
❖ Policy, Management and Organisation in International Public Health
❖ Clinical Pharmacology for Exchange Students.
❖ Structure-based drug design
❖ Cellular Immunology
❖ Advanced Microscopy
Competence
Design, Writing, Research, Exchange, Management, Scientific Writing, Life Science, It, Transformation, Development, Health, International, Organization, Science, Internship
My education
2010
-
2017
Academic Medical Center University of Amsterdam
Doctorate, N/a
Doctorate, N/a
2008
-
2010
Biosciences Åbo Akademie University
MSc, N/a
MSc, N/a
2007
-
2008
Rovaniemi University of Applied Sciences
Somepostgraduate, International Project Management
Somepostgraduate, International Project Management
2001
-
2005
University of Yaoundé
BSc, Biology and Physiology
BSc, Biology and Physiology
Laurel's reviews
Laurel has not received any reviews on Worksome.
Contact Laurel Tabe Bate-Eya, PhD
Worksome removes the expensive intermediaries and gives you direct contact with relevant talent.
Create a login and get the opportunity to write to Laurel directly in Worksome.
are ready to help you
and get specific bids from skilled talent in Denmark